Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Phase 3

Not yet recruiting

• Conditions: Gastric Cancer
• Interventions: Drug: Envolimab; Drug: Fruquintinib; Drug: Oxaliplatin; Drug: Tegafur

• Registration Number: NCT05914610
• Lead Sponsor: Fujian Medical University

Brief Summary

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-27
• Study First Submitted QC: 2023-06-13
• Study First Posted: 2023-06-22
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-23
• Last Update Posted: 2023-08-25
• Study Start: 2023-09-01
• Primary Completion: 2025-07-30
• Study Completion: 2028-07-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Age: 18-75 years of age;

2. Pathological (including histological or cytological) confirmation of gastric adenocarcinoma;

3. Before surgery, CT/MRI, PET-CT, if necessary, laparoscopic exploration to determine the clinical stage of T4bN0M0 and TanyN2-3M0, and determined by researchers that the local advanced patients can not be resectable;

4. At least one measurable detected by CT examination in accordance with the RECIST1.1

5. ECOG#Eastern Cooperative Oncology Group#PS#Performance Status#:0-1 scores;

6. The expected survival time is more than 3 months

7. The main organ function is normal, which should meet the following criteria:

   #1#blood routine examination standards should be met#no blood transfusion within 14 days#

   a.HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L #2#biochemical examination shall comply with the following criteria#

   1. BIL#1.5 normal upper limit ULN
   2. ALT and AST#2.5 ULN
   3. Cr≤1 ULN#CCR#creatinine clearance rate##60ml/min(Cockcroft Gault formula)

8. Women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test#

9. No other clinical studies were conducted before and during the treatment

10. Participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up

Exclusion Criteria

1. Imaging or intraoperative exploration found patients with peritoneum, liver, lung and other distant metastases
2. Patients with allergies or suspected allergies to study drugs or similar drugs
3. Confirmed HER-2 positive patients
4. Other malignancies in the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix
5. Live vaccine was administered within 4 weeks prior to enrolling or possibly during the study period
6. Had an active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment
7. Past recipients of allogeneic bone marrow transplants or organ transplants
8. Patient has any current disease or condition that affects drug absorption, or the patient is unable to take the drug orally
9. The blood pressure of patients with hypertension cannot be reduced to the normal range by the one antihypertensive drugs (systolic pressure ≥150 mmHg, diastolic pressure ≥100 mmHg) or hard to controled by two or more antihypertensive drugs
10. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g)
11. The patient currently has gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectosed tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation
12. Patients with significant evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, black stool, blood in stool), hemoptysis (within 4 weeks >5 mL fresh blood) or a thromboembolic event (including stroke and/or transient ischemic attack) within 12 months
13. Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure more than class II ; Ventricular arrhythmias requiring medical treatment; An electrocardiogram (ECG) showed a QT c interval ≥480 milliseconds
14. Active or uncontrolled severe infection (≥CTCAE grade 2 infection)
15. A history of human immunodeficiency virus (HIV) infection or clinically significant liver disease, including viral hepatitis [active HBV infection must be ruled out as a known carrier of hepatitis B virus (HBV), i.e. positive HBV DNA (>1×104 copies /mL or >2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis]
16. The researchers consider those who were not suitable for inclusion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Envolimab + fruquinitinib +SOX regimen	Oxaliplatin	-
Envolimab + fruquinitinib +SOX regimen	Fruquintinib	-
Envolimab + fruquinitinib +SOX regimen	Tegafur	-
SOX regimen	Oxaliplatin	-
Envolimab + fruquinitinib +SOX regimen	Envolimab	-
SOX regimen	Tegafur	-

Primary Outcome Measures

Name	Time	Method
Surgical conversion rate	2-3 months	Defined as the proportion of patients who have undergone surgical resection after multidisciplinary assessment after completing 4-6 cycles of conversion therapy

Secondary Outcome Measures

Name	Time	Method
Pathological complete response (pCR)	4 months	Measured as the proportion of participants with a pathological complete response at the time of definitive surgery.
Median survival time	3 years	The time from enrollment to the time when only 50% of the individuals alive
Objective response rate (ORR)	4 months	Defined as the percentage of the participants in the analysis population who had a confirmed patial response and complete reponse according to RECIST 1.1 based on investigator assessment
R0 resection rate	2-3 month	Defined as no residue under the microscope after resection
Adverse event (AEs)	2 years	Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The number of Participants with adverse events will be recorded at each treatment visit.
Median disease free survival (DFS) time	3 years	The time from opreation to the time when only 50% of the individuals had no relapse or tumor progression
3-year DFS rate	3 years
1-year DFS rate	1 year
Major pathological response rate (MPR)	4 months	The proportion of participants with a major pathological response (mPR) at the time of definitive surgery.
Quality of life (QOL)	2 years	The quality of life of patients during treatment is eveluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3.0)